Intanza

RSS

Withdrawn

This medicine's authorisation has been withdrawn

influenza vaccine (split virion, inactivated)
MedicineHumanWithdrawn

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 3 August 2018, the European Commission withdrew the marketing authorisation for Intanza (influenza vaccine (split virion, inactivated)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Pasteur Europe, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Intanza was granted marketing authorisation in the EU on 24 February 2009 for prophylaxis of influenza in individuals 60 years of age and over. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2013. There are other medicinal products similar to Intanza authorised and marketed in the EU. 

The European Public Assessment Report (EPAR) for Intanza is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (637.89 KB - PDF)

Vaata

español (ES) (545.64 KB - PDF)

Vaata

čeština (CS) (611.73 KB - PDF)

Vaata

dansk (DA) (545.52 KB - PDF)

Vaata

Deutsch (DE) (547.47 KB - PDF)

Vaata

eesti (ET) (552.93 KB - PDF)

Vaata

ελληνικά (EL) (635.18 KB - PDF)

Vaata

français (FR) (547.7 KB - PDF)

Vaata

hrvatski (HR) (567.46 KB - PDF)

Vaata

italiano (IT) (544.82 KB - PDF)

Vaata

latviešu (LV) (610.29 KB - PDF)

Vaata

lietuvių (LT) (570.94 KB - PDF)

Vaata

magyar (HU) (605.73 KB - PDF)

Vaata

Malti (MT) (615.9 KB - PDF)

Vaata

Nederlands (NL) (545.14 KB - PDF)

Vaata

polski (PL) (608.34 KB - PDF)

Vaata

português (PT) (545.74 KB - PDF)

Vaata

română (RO) (571.27 KB - PDF)

Vaata

slovenčina (SK) (613.61 KB - PDF)

Vaata

slovenščina (SL) (601.13 KB - PDF)

Vaata

suomi (FI) (544.59 KB - PDF)

Vaata

svenska (SV) (545.64 KB - PDF)

Vaata

Product information

български (BG) (1.47 MB - PDF)

Vaata

español (ES) (1 MB - PDF)

Vaata

čeština (CS) (1.31 MB - PDF)

Vaata

dansk (DA) (974.04 KB - PDF)

Vaata

Deutsch (DE) (1.01 MB - PDF)

Vaata

eesti (ET) (965.77 KB - PDF)

Vaata

ελληνικά (EL) (1.7 MB - PDF)

Vaata

français (FR) (839.69 KB - PDF)

Vaata

hrvatski (HR) (992.86 KB - PDF)

Vaata

italiano (IT) (951.14 KB - PDF)

Vaata

latviešu (LV) (1.25 MB - PDF)

Vaata

lietuvių (LT) (891.45 KB - PDF)

Vaata

magyar (HU) (1.44 MB - PDF)

Vaata

Malti (MT) (1.5 MB - PDF)

Vaata

Nederlands (NL) (980.56 KB - PDF)

Vaata

polski (PL) (1.22 MB - PDF)

Vaata

português (PT) (783.19 KB - PDF)

Vaata

română (RO) (875.4 KB - PDF)

Vaata

slovenčina (SK) (1.6 MB - PDF)

Vaata

slovenščina (SL) (1.53 MB - PDF)

Vaata

suomi (FI) (785.83 KB - PDF)

Vaata

svenska (SV) (779.44 KB - PDF)

Vaata

Íslenska (IS) (1.02 MB - PDF)

Vaata

norsk (NO) (1004.45 KB - PDF)

Vaata
Latest procedure affecting product information:II/0054
07/09/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (566.72 KB - PDF)

Vaata

español (ES) (540.21 KB - PDF)

Vaata

čeština (CS) (546.42 KB - PDF)

Vaata

dansk (DA) (539.59 KB - PDF)

Vaata

Deutsch (DE) (531.18 KB - PDF)

Vaata

eesti (ET) (539.24 KB - PDF)

Vaata

ελληνικά (EL) (567.85 KB - PDF)

Vaata

français (FR) (506.88 KB - PDF)

Vaata

hrvatski (HR) (543.3 KB - PDF)

Vaata

italiano (IT) (540.42 KB - PDF)

Vaata

latviešu (LV) (557.31 KB - PDF)

Vaata

lietuvių (LT) (524.28 KB - PDF)

Vaata

magyar (HU) (556.81 KB - PDF)

Vaata

Malti (MT) (549.14 KB - PDF)

Vaata

Nederlands (NL) (531.06 KB - PDF)

Vaata

polski (PL) (548.37 KB - PDF)

Vaata

português (PT) (530.41 KB - PDF)

Vaata

română (RO) (532.7 KB - PDF)

Vaata

slovenčina (SK) (548.64 KB - PDF)

Vaata

slovenščina (SL) (544.53 KB - PDF)

Vaata

suomi (FI) (538.06 KB - PDF)

Vaata

svenska (SV) (529.92 KB - PDF)

Vaata

Íslenska (IS) (540.06 KB - PDF)

Vaata

norsk (NO) (530.41 KB - PDF)

Vaata

Product details

Name of medicine
Intanza
Active substance
influenza virus (inactivated, split) of the following strains:A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)
International non-proprietary name (INN) or common name
influenza vaccine (split virion, inactivated)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BB02

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.
The use of Intanza should be based on official recommendations.

Authorisation details

EMA product number
EMEA/H/C/000957
Marketing authorisation holder
Sanofi Pasteur Europe

2 Avenue Pont Pasteur
69007 Lyon
France

Marketing authorisation issued
24/02/2009
Withdrawal of marketing authorisation
03/08/2018
Revision
18

Assessment history

This page was last updated on

Share this page